Company announcementCompany-reported
What was reported
MIAMI, Fla., October 26, 2026 -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced updated results from ELPIS II following planned additional analysis conducted by the Company and the National Institutes of Health (NIH) funded trial investigators.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Oct 26, 2026 · Open the source ↗
What the evidence supports
Longeveron furnished a press release to the SEC (Form 8-K, Item 8.01) about a company announcement. It shows what the company chose to disclose on that date.
What remains unknown
Claims in the release are the company's own and have not been independently verified. Furnishing a document to the SEC does not mean the SEC reviewed or endorsed it.
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineLongeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Oct 26, 2026 · Open the source ↗
Press release lead paragraphMIAMI, Fla., October 26, 2026 -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced updated results from ELPIS II following planned additional analysis conducted by the Company and the National Institutes of Health (NIH) funded trial investigators.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Oct 26, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:55 UTC
Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.